Desmopressin and other synthetic vasopressin analogues in cancer treatment.
Desmopressin (DDAVP) is a well tolerated and convenient haemostatic agent that can be used in a number of clinical conditions with bleeding diathesis. It has several effects on the haemostatic system, causing endogenous release of coagulation factor VIII, von Willebrand factor and tissue-type plasminogen activator, among others. In this review we present a growing body of evidence showing that DDAVP treatment may impair spread of cancer cells and contribute to encapsulation of tumour tissue. Our data in preclinical animal models suggest a potential application of DDAVP in the perioperative management of aggressive solid tumours. Novel vasopressin analogues with improved antitumor effects are currently in development.
Gomez
Daniel E
DE
Laboratory of Molecular Oncology, Department of Science and Technology Quilmes National University, R. Saenz Peña 180, Bernal (1876), Buenos Aires, Argentina. degomez@unq.edu.ar
Ripoll
Giselle V
GV
Girón
Santiago
S
Alonso
Daniel F
DF
D000818:Animals; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D009361:Neoplasm Invasiveness; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014667:Vasopressins / Q000627:therapeutic use
D006490:Hemostatics; D014667:Vasopressins; D003894:Deamino Arginine Vasopressin